0000919574-18-008127.txt : 20181221
0000919574-18-008127.hdr.sgml : 20181221
20181221181624
ACCESSION NUMBER: 0000919574-18-008127
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181220
FILED AS OF DATE: 20181221
DATE AS OF CHANGE: 20181221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kovner Bruce
CENTRAL INDEX KEY: 0001325713
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37569
FILM NUMBER: 181250827
MAIL ADDRESS:
STREET 1: C/O CAXTON ASSOCIATES
STREET 2: 500 PARK AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CAXTON CORP
CENTRAL INDEX KEY: 0001388551
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37569
FILM NUMBER: 181250828
BUSINESS ADDRESS:
STREET 1: 731 ALEXANDER ROAD
STREET 2: BUILDING 2, SUITE 500
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-419-1800
MAIL ADDRESS:
STREET 1: 731 ALEXANDER ROAD
STREET 2: BUILDING 2, SUITE 500
CITY: PRINCETON
STATE: NJ
ZIP: 08540
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CDK ASSOCIATES, L.L.C.
CENTRAL INDEX KEY: 0001576081
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37569
FILM NUMBER: 181250829
BUSINESS ADDRESS:
STREET 1: C/O CAXTON CORPORATION
STREET 2: 731 ALEXANDER ROAD, BUILDING #2
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-419-1800
MAIL ADDRESS:
STREET 1: C/O CAXTON CORPORATION
STREET 2: 731 ALEXANDER ROAD, BUILDING #2
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Strongbridge Biopharma plc
CENTRAL INDEX KEY: 0001634432
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 981130690
STATE OF INCORPORATION: L2
BUSINESS ADDRESS:
STREET 1: 900 NORTHBROOK DRIVE, SUITE 200
CITY: TREVOSE
STATE: PA
ZIP: 19053
BUSINESS PHONE: (610) 254-9200
MAIL ADDRESS:
STREET 1: 900 NORTHBROOK DRIVE, SUITE 200
CITY: TREVOSE
STATE: PA
ZIP: 19053
FORMER COMPANY:
FORMER CONFORMED NAME: Cortendo AB
DATE OF NAME CHANGE: 20150219
4
1
ownership.xml
X0306
4
2018-12-20
0
0001634432
Strongbridge Biopharma plc
SBBP
0001576081
CDK ASSOCIATES, L.L.C.
C/O CAXTON CORPORATION
731 ALEXANDER ROAD, BLDG. 2
PRINCETON
NJ
08540
0
0
1
0
0001388551
CAXTON CORP
731 ALEXANDER ROAD
BUILDING 2
PRINCETON
NJ
08540
0
0
1
0
0001325713
Kovner Bruce
C/O CAXTON CORPORATION
731 ALEXANDER ROAD, BLDG. 2
PRINCETON
NJ
08540
0
0
1
0
Ordinary Shares, $0.01 par value
2018-12-20
4
P
0
146467
3.9967
A
6441296
D
Ordinary Shares, $0.01 par value
2018-12-21
4
P
0
90612
3.9508
A
6531908
D
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.85 to $4.22 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
Following the transactions reported herein, these shares represent (a) 6,196,882 Ordinary Shares that are owned directly by CDK Associates, LLC, which is a reporting person, and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation, the manager of CDK Associates, LLC, and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation; and (b) 335,026 Ordinary Shares beneficially owned by employees of an affiliate of Caxton Corporation and may be deemed to be indirectly beneficially owned by (i) Caxton Corporation and (ii) Bruce Kovner, the chairman and sole shareholder of Caxton Corporation.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.82 to $4.10 per share, inclusive. The Reporting Persons undertake to provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price.
Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
CDK Associates, L.L.C., By: Caxton Corporation, its Manager,By: /s/ Heath Weisberg, General Counsel
2018-12-21
Caxton Corporation, By: /s/ Heath Weisberg, General Counsel
2018-12-21
By: /s/ Heath Weisberg, Attorney-in-Fact
2018-12-21